Sanofi Touts Long-Term AYVAKIT Data
A Sanofi subsidiary, Blueprint Medicines, has announced four-year data from its PIONEER study on the drug AYVAKIT. The results show a sustained benefit and long-term safety for patients with indolent systemic mastocytosis, a rare blood disorder.
AYVAKIT is a targeted therapy designed to inhibit the KIT D816V mutation, the primary driver in approximately 95% of indolent systemic mastocytosis cases. The U.S. Food and Drug Administration approved it for this condition in May 2023, marking a shift from managing symptoms to treating the underlying cause of the disease. The PIONEER study is a three-part trial that included a randomized, double-blind, placebo-controlled phase. The long-term data comes from an open-label extension where patients, including those initially on placebo, could receive AYVAKIT. After a median treatment duration of 40 months, patients showed sustained and deep improvements in their overall symptoms. The mean Total Symptom Score, on a scale of 0-110, was reduced by about 20 points from a baseline of 48. These improvements were seen across skin, gastrointestinal, and neurocognitive symptom categories. The long-term safety profile remains favorable. With a median follow-up of over three years, the discontinuation rate due to treatment-related adverse events was low at 3%. The most common side effect reported was mild edema. Beyond symptom control, long-term treatment with AYVAKIT has shown improvements in bone health. In a subset of patients, an increase in mean bone mineral density was observed in the lumbar spine and hip at both one and three years of treatment, regardless of the use of other bone-strengthening medications.
